VCEL
HEALTHCAREVericel Corp
$36.78-0.03 (-0.08%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VCEL Today?
No stock-specific AI insight has been generated for VCEL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$28.95$45.97
$36.78
Fundamentals
Market Cap$1.9B
P/E Ratio114.9
EPS$0.32
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume829K
Avg Volume (10D)—
Shares Outstanding50.9M
VCEL News
20 articles- Vericel Q1 Earnings Call HighlightsMarketbeat·May 9, 2026
- Vericel (VCEL) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceYahoo Finance·May 7, 2026
- Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a BetYahoo Finance·May 4, 2026
- Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC AuditorMarketbeat·May 1, 2026
- Exploring Three High Growth Tech Stocks In The US MarketYahoo Finance·Apr 29, 2026
- Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 23, 2026
- MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionYahoo Finance·Apr 2, 2026
- Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBridYahoo Finance·Apr 2, 2026
- What Makes Vericel Corporation (VCEL) an Investment Bet?Yahoo Finance·Mar 13, 2026
- Will FDA Approval of Burlington MACI Manufacturing Shift Vericel's (VCEL) Long-Term Growth NarrativeYahoo Finance·Mar 10, 2026
- FDA MACI Approval Tests Vericel’s Capacity Plans And Growth StoryYahoo Finance·Mar 10, 2026
- Vericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACIYahoo Finance·Mar 10, 2026
- Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing FacilityYahoo Finance·Mar 4, 2026
- Vericel to Present at Multiple Upcoming Investor ConferencesYahoo Finance·Mar 3, 2026
- MediWound Updates NexoBrid Growth, EscharEx Phase III Timeline and BARDA Talks at Oppenheimer ConferenceMarketbeat·Mar 1, 2026
- A Look At Vericel (VCEL) Valuation After Record 2025 Results And Upbeat 2026 Growth GuidanceYahoo Finance·Feb 28, 2026
- Vericel Q4 Earnings Call HighlightsMarketbeat·Feb 27, 2026
- Vericel Corporation Q4 2025 Earnings Call SummaryMoby·Feb 27, 2026
All 20 articles loaded
Price Data
Open$34.73
Previous Close$36.81
Day High$36.07
Day Low$33.92
52 Week High$45.97
52 Week Low$28.95
52-Week Range
$28.95$45.97
$36.78
Fundamentals
Market Cap$1.9B
P/E Ratio114.9
EPS$0.32
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume829K
Avg Volume (10D)—
Shares Outstanding50.9M
About Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—